Revenio Group Corporation, Stock Exchange Release, February 23, 2015 at 13:40
REVENIO GROUP CORPORATION PUBLISHES ANNUAL REPORT 2015
Today, Revenio Group Corporation published the annual report for 2015. The AR, available in Finnish in PDF format on the corporations' website at www.revenio.fi, contains financial statements for the corporation and parent company, the report of the Board of Directors, auditors report and a report on corporate governance.
The AR will be published in print in week 11. To order a copy, place an order with Revenio Group Corporation, Äyritie 22, FI-01510 Vantaa, tel. +358 50 382 0131 or by e-mail elina.kari@revenio.fi.
Revenio Group Corporation
Olli-Pekka Salovaara
President and CEO
For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi
DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims at developing even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2015, the Revenio Group's net sales totaled MEUR 20.3, with its operating margin for continuing operations standing at 28.4%. Revenio Group Corporation is listed on Nasdaq Helsinki.
HUG#1988336
